GLP-1 medications are known for quieting the food noise, meaning that they reduce the constant thoughts about eating, along with increasing satiety
Diabetes contributes to disease progression in HF and is associated with worse prognosis, even when guideline recommended HF therapies are utilized [6,7]
The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial, or legal advice
Postoperative adjuvant EBRT to the neck and mediastinum should be considered in patients at high risk for airway obstruction and local recurrence, such as residual disease, extensive LN metastases, or extra-thyroidal extension as an expert opinion of ATA guidelines [1]
Keep reading to learn how cost can create barriers to weight loss treatment, and how providers can address these concerns through transparent cost conversations and patient financing options
The promise and peril of GLP-1 agonists: What we do (and don't) know as of August 2024 Yulan Egan Aug 21, 2024 6 min read Across the past two years, GLP-1 agonistsa class of drugs that treat type 2 diabetes (T2D) and obesityhave not only become a major source of industry discourse, but a household name
